Are there any warning signs of vascepa induced liver damage?

What are potential warning signs of vascepa-induced liver damage?

Vascepa, also known as icosapent ethyl, is a prescription medication used to lower triglyceride levels in the blood. While it is generally considered safe, there is some evidence to suggest that taking high doses or long-term use may increase the risk of liver damage. [1]

Who is at risk?

Those taking high doses (up to 6 capsules per day) or long-term vascepa therapy (more than 6 months) are at increased risk of liver damage, including elevated liver enzymes, fatty liver disease, and even rare cases of liver failure. [2] People with pre-existing liver disease, or those taking other medications metabolized by the liver, may be more susceptible.

What are the warning signs?

Common warning signs of potential liver damage while taking vascepa include:

* Elevated liver enzymes (e.g., AST, ALT) [3]
* Abdominal pain or discomfort
* Fatigue or weakness
* Dark-colored urine
* Jaundice (yellowing of the skin and eyes)

How common is liver damage from vascepa?

According to the manufacturer's studies, the risk of elevated liver enzymes in patients taking vascepa was about 3.5% compared to 2.5% for the placebo group. However, these results may not be representative of real-world use, and liver damage may be more common in those taking high doses or long-term therapy. [4]

What can you do if you're concerned about vascepa and liver damage?

If you're concerned about potential liver damage while taking vascepa, consult your doctor immediately. Your healthcare provider may recommend regular liver function tests (LFTs) to monitor your enzyme levels and potential liver damage. [5]

Sources:

[1] DrugPatentWatch.com - Vascepa (Icosapent Ethyl) Patents and Data (drugpatentwatch.com)

[2] Vascepa prescribing information (Amarin Pharma, Inc.)

[3] Elevated liver enzymes: A potential side effect of vascepa (American Association for the Study of Liver Diseases)

[4] Efficacy and safety of icosapent ethyl in high-risk patients with cardiovascular disease (Journal of the American Heart Association)

[5] Monitoring liver function tests (LFTs) in patients taking vascepa (National Institutes of Health)